BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22824752)

  • 1. pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.
    Sozio P; Rapino M; Di Valerio V; Laserra S; Pacella S; Di Stefano A; Cataldi A
    J Biol Regul Homeost Agents; 2012; 26(2):245-51. PubMed ID: 22824752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
    Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
    J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
    Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
    Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
    Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
    J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. γ-Secretase component presenilin is important for microglia β-amyloid clearance.
    Farfara D; Trudler D; Segev-Amzaleg N; Galron R; Stein R; Frenkel D
    Ann Neurol; 2011 Jan; 69(1):170-80. PubMed ID: 21280087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
    Phiel CJ; Wilson CA; Lee VM; Klein PS
    Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
    Schor NF
    Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
    Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes.
    Sharples RA; Vella LJ; Nisbet RM; Naylor R; Perez K; Barnham KJ; Masters CL; Hill AF
    FASEB J; 2008 May; 22(5):1469-78. PubMed ID: 18171695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
    Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
    J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
    Peters JU; Galley G; Jacobsen H; Czech C; David-Pierson P; Kitas EA; Ozmen L
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5918-23. PubMed ID: 17869099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
    Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y
    Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-β.
    Andreyeva A; Nieweg K; Horstmann K; Klapper S; Müller-Schiffmann A; Korth C; Gottmann K
    Brain; 2012 Jul; 135(Pt 7):2140-54. PubMed ID: 22637581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.